A Rapid, Simple, Specific, Accurate, Precise and Reproducible validated RP- HPLC method for the estimation of Lurasidone Hydrochloride in the Bulk and Pharmaceutical dosage form. RP-HPLC analysis was carried out using Acetonitrile: Methanol: Acetic Acid (30:45:25) mobile phase and Inertsil C 18 ODS-3V column (250 mm x 4.6 mm, 5.0 i particle size) as stationary phase with detection wavelength of 254 nm utilising Shimadzu HPLC (LC2010HT) equipped with UV-Visible Detector. Linearity was obtained in the concentration range of 10-60 µg/ml for Lurasidone Hydrochloride. The retention time for Lurasidone Hydrochloride was 3.19 ± 0.11 minutes. The % recovery of the drug was found to be 99.23 – 101.27 %. LOD and LOQ were found to be 1.9700 and 5.9698 ig/ml at 254 nm respectively for Lurasidone Hydrochloride . The method was found to be precise with RSD 0.09 – 0.13 for intraday (n=3) and RSD 0.10 - 0.19 for interday (n=3) for Lurasidone Hydrochloride Method was statistically validated for Accuracy, Precision, Specificity, LOQ, Robustness and Ruggedness according to ICH guidelines and can be used for routine analysis of Pharmaceutical dosage form.
[1]
M. Sanford.
Lurasidone : in the treatment of schizophrenia.
,
2013,
CNS drugs.
[2]
Kyeong-Ryoon Lee,et al.
Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats
,
2011,
Xenobiotica; the fate of foreign compounds in biological systems.
[3]
L. Citrome.
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
,
2011,
Clinical schizophrenia & related psychoses.
[4]
Hitomi Oki,et al.
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
,
2010,
Journal of Pharmacology and Experimental Therapeutics.
[5]
Mitsutaka Nakamura,et al.
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-HT 7 and 5-HT 1A Receptor Activity
,
2010
.